[Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine]

Area of Science:

• Oncology
• Urothelial Carcinoma Research
• Pharmacological Treatments

Background:

• Urothelial carcinoma of the bladder is an aggressive cancer with poor survival rates in advanced stages.
• Current treatments, including immune checkpoint inhibitors, benefit less than 30% of patients, lacking predictive biomarkers.
• Vinflunine, a vinca-alkaloid, is an approved second-line therapy for advanced urothelial carcinoma.

Purpose of the Study:

• To review the efficacy of vinflunine in advanced urothelial carcinoma.
• To advocate for the reimbursement of vinflunine based on clinical trial data.
• To support patient and clinician requests for vinflunine re-access.

Main Methods:

• Review of phase III clinical trial data for immunotherapies.
• Analysis of vinflunine's role as a second-line treatment post-platinum therapy.
• Compilation of arguments for vinflunine reimbursement.

Main Results:

• Vinflunine is the only agent approved after phase III trials for advanced urothelial carcinoma.
• Despite its approval, vinflunine has been withdrawn from reimbursement lists, limiting its use.
• Phase III trial data supports vinflunine's efficacy in this patient population.

Conclusions:

• Vinflunine remains a critical treatment option for advanced or metastatic urothelial carcinoma.
• Reimbursement of vinflunine is essential to ensure patient access to effective therapy.
• Further consideration of vinflunine's place in treatment guidelines is warranted.